N4 Pharma Plc Share News (N4P)

UK earnings, trading statements calendar - next 7 days

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

N4 Pharma plummets on broker offer to raise up to GBP1 million

(Alliance News) - N4 Pharma PLC shares plummeted on Friday, after it raised GBP1.0 million through a placing of 50.0 million shares and announced a broker offer to raise up to GBP1.0 million.

N4 Pharma shares tumble following placing, broker offer announcement

(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.

IN BRIEF: N4 Pharma expands patent application claims for Nuvec

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.

N4 Pharma reports success in recent 'Nuvec' testing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

N4 Pharma announces successful test in next stage of Nuvec development

(Alliance News) - N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

N4 Pharma reduces losses as Nuvec development continues

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.

IN BRIEF: N4 completes testing on loading Nuvec drug with siRNA probes

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".

TRADING UPDATES: Premier Miton assets dip; Challenger Energy CFO quits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: